TG Therapeutics Inc

1TGTX

Company Profile

  • Business description

    TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

  • Contact

    3020 Carrington Mill Boulevard
    Suite 475
    MorrisvilleNC27560
    USA

    T: +1 212 554-4484

    E: [email protected]

    https://www.tgtherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    338

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,365.7024.700.30%
CAC 407,593.8738.000.50%
DAX 4022,496.9871.150.32%
Dow JONES (US)40,877.68208.320.51%
FTSE 1008,485.219.64-0.11%
HKSE22,119.41111.300.51%
NASDAQ17,780.26333.921.91%
Nikkei 22536,452.30406.921.13%
NZX 50 Index12,148.60245.292.06%
S&P 5005,624.6955.631.00%
S&P/ASX 2008,145.6019.400.24%
SSE Composite Index3,279.037.62-0.23%

Market Movers